The long-awaited alternative to Coumadin (warfarin) has just been approved by the US FDA. The FDA just approved Pradaxa (dabigatran) for use by those with atrial fibrillation for preventing afib-related strokes.
The FDA based approval on results of the RE-LY trial, which saw patients on Pradaxa having fewer strokes than those on warfarin. And Pradaxa doesn’t require the monitoring nor the restrictive diet that warfarin does.
Learn more at: